Livingston, NJ, United States of America

Achyutharao Sidduri

This inventor holds 33 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Drug Delivery Systems. Top assignees: Hoffmann-La Roche Inc., European Molecular Biology Laboratory, F. Hoffmann-La Roche Ag. Active years: 2001-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Achyutharao Sidduri. Retrieved from https://idiyas.com/inventor/achyutharao-sidduri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 8)

% Patents Active = 30.3

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 19)

Average Co-Inventor Count = 3.0

ph-index = 9

Forward Citations = 200(Granted Patents)

Location History:

West Orange, NJ (US) (2013 - 2017)
Livingston, NJ (US) (2001 - 2022)
Newark, NJ (US) (2015 - 2024)

Company Filing History:

26 out of 5,026

Hoffmann-La Roche Inc.

patents

3 out of 79

European Molecular Biology Laboratory

patents

3 out of 181

F. Hoffmann-La Roche Ag

patents

4. 3 out of 8

Savira Pharmaceuticals Gmbh

Rutgers, The State University of New Jersey

patents

where one patent can have more than one assignee

Years Active: 2001-2024

Loading Chart...

Areas of Expertise:

Integrin Antagonists

Drug Delivery

Viral Disease Treatment

Endonuclease Inhibitors

Kinase Modulators

LPAR Antagonists

Naphthylacetic Acids

Glucokinase Activators

Leukotriene Inhibitors

Azaindole Compounds

Thiazolinone Derivatives

Pyrimidone Derivatives

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11964987 - Isoidide derivatives and methods of making and using same (2024-04-23),

2. 11491178 - Chitosan covalently linked with small molecule integrin antagonist for targeted delivery (2022-11-08),

3. 10815244 - Isoidide derivatives and methods of making and using same (2020-10-27),

4. 9650363 - Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1 (2017-05-16),

5. 9586916 - Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 (2017-03-07),

6. 9505758 - Substituted 1,5-naphthyridines as endonuclease inhibitors (2016-11-29),

7. 9447035 - Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 (2016-09-20),

8. 9321738 - N-alkyltriazole compounds as LPAR antagonists (2016-04-26),

9. 9199987 - Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease (2015-12-01),

10. 9169215 - LPAR—substituted cyanopyrazole compounds (2015-10-27),

11. 9045486 - Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease (2015-06-02),

12. 9000044 - Substituted naphthylacetic acids (2015-04-07),

13. 8962622 - Benzotriazole kinase modulators (2015-02-24),

14. 8691993 - Piperidinyl naphthylacetic acids (2014-04-08),

15. 8658646 - Pyrrolopyrazine kinase inhibitors (2014-02-25),

Title: Achyutharao Sidduri: Innovator in Pharmaceutical Sciences

Introduction

Achyutharao Sidduri, based in Livingston, NJ, is a prolific inventor known for his contributions to pharmaceutical innovations. With an impressive portfolio of 33 patents, Sidduri has made significant advancements in the field of drug formulation and delivery systems, particularly through the development of novel compounds with enhanced bioavailability.

Latest Patents

Sidduri's latest patents include inventions that focus on isoindide derivatives, which offer improved solubility and bioavailability. These compounds are designed to effectively inhibit various biological targets such as macrophage migration inhibitory factor (MIF) and epidermal growth factor receptor (EGFR). Additionally, one of his notable inventions involves chitosan polymer derivatives. These innovative chitosan-based formulations target integrin dimers, providing an efficient delivery mechanism for therapeutic compounds to specific tissues or cells.

Career Highlights

Throughout his career, Achyutharao Sidduri has collaborated and worked with esteemed companies in the pharmaceutical industry. His experience includes roles at Hoffmann-La Roche Inc. and Savira Pharmaceuticals GmbH, where he contributed to various drug development projects. His work has laid the groundwork for future innovations in biopharmaceuticals and targeted therapy.

Collaborations

Sidduri has worked alongside notable figures in the industry, including Jefferson Wright Tilley and Robert Alan Goodnow, Jr. These collaborations have helped amplify the impact of his research and inventions, fostering advancements in pharmaceutical sciences and therapeutic applications.

Conclusion

Achyutharao Sidduri stands as a significant figure in the realm of pharmaceuticals, with his extensive patent portfolio reflecting his dedication to innovation. His research into compounds that enhance drug delivery marks an important step forward in the quest for more effective and targeted therapies.

Profile summary based on public USPTO records.